The clinical community is keenly watching this innovative therapy, a unique agonist targeting both glucose metabolism and another incretin hormone. Preliminary data suggest it may offer significant improvements in obesity management compared to traditional therapies, potentially representing a important breakthrough in the battle of obesity. Furthe